These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 1335646)
21. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. André FE; D'Hondt E; Delem A; Safary A Vaccine; 1992; 10 Suppl 1():S160-8. PubMed ID: 1335652 [TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later. Briem H; Safary A J Med Virol; 1994 Dec; 44(4):443-5. PubMed ID: 7897378 [TBL] [Abstract][Full Text] [Related]
23. Safety and immunogenicity of a new formulation of an inactivated hepatitis A vaccine. Dagan R; Greenberg D; Goldenbertg-Gehtman P; Vidor E; Briantais P; Pinsk V; Athias O; Dumas R Vaccine; 1999 Apr; 17(15-16):1919-25. PubMed ID: 10217590 [TBL] [Abstract][Full Text] [Related]
24. Brief report: hepatitis A vaccination in Greek military recruits. Papaevangelou G; Totos G; Roumeliotou A; Safary A J Med Virol; 1993 May; 40(1):1-4. PubMed ID: 8390557 [TBL] [Abstract][Full Text] [Related]
25. Vaccination against hepatitis A: comparison of different short-term immunization schedules. Jilg W; Bittner R; Bock HL; Clemens R; Schätzl H; Schmidt M; André FE; Deinhardt F Vaccine; 1992; 10 Suppl 1():S126-8. PubMed ID: 1335642 [TBL] [Abstract][Full Text] [Related]
26. Clinical and laboratory observations following oral or intramuscular administration of a live attenuated hepatitis A vaccine candidate. Sjogren MH; Purcell RH; McKee K; Binn L; Macarthy P; Ticehurst J; Feinstone S; Caudill J; See A; Hoke C Vaccine; 1992; 10 Suppl 1():S135-7. PubMed ID: 1335645 [TBL] [Abstract][Full Text] [Related]
27. Hepatitis A vaccine. Bader TF Am J Gastroenterol; 1996 Feb; 91(2):217-22. PubMed ID: 8607483 [TBL] [Abstract][Full Text] [Related]
28. Characterization of the immune response of volunteers vaccinated with a killed vaccine against hepatitis A. Delem A; Safary A; De Namur F; Hauser P; D'Hondt E Vaccine; 1993; 11(4):479-84. PubMed ID: 8385844 [TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease. Lee SD; Chan CY; Yu MI; Wang YJ; Chang FY; Lo KJ; Safary A J Med Virol; 1997 Jun; 52(2):215-8. PubMed ID: 9179771 [TBL] [Abstract][Full Text] [Related]
30. Effect of postexposure vaccination in a chimpanzee model of hepatitis A virus infection. Robertson BH; D'Hondt EH; Spelbring J; Tian H; Krawczynski K; Margolis HS J Med Virol; 1994 Jul; 43(3):249-51. PubMed ID: 7931186 [TBL] [Abstract][Full Text] [Related]
31. Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity. Van Damme P; Matheï C; Thoelen S; Meheus A; Safary A; André FE J Med Virol; 1994 Dec; 44(4):435-41. PubMed ID: 7897376 [TBL] [Abstract][Full Text] [Related]
32. Clinical experience with an inactivated hepatitis A vaccine. Clemens R; Safary A; Hepburn A; Roche C; Stanbury WJ; André FE J Infect Dis; 1995 Mar; 171 Suppl 1():S44-9. PubMed ID: 7876648 [TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study. Goilav C; Zuckerman J; Lafrenz M; Vidor E; Lauwers S; Ratheau C; Benichou G; Zuckerman A J Med Virol; 1995 Jul; 46(3):287-92. PubMed ID: 7561805 [TBL] [Abstract][Full Text] [Related]
34. Single dose-inactivated hepatitis A vaccination schedule for susceptible youngsters. Lee SD; Chan CY; Yu MI; Wang YJ; Lo KJ; Safary A Am J Gastroenterol; 1996 Jul; 91(7):1360-2. PubMed ID: 8677995 [TBL] [Abstract][Full Text] [Related]
35. Clinical and immunological investigation of a new combined hepatitis A and hepatitis B vaccine. Ambrosch F; Wiedermann G; André FE; Delem A; Gregor H; Hofmann H; D'Hondt E; Kundi M; Wynen J; Kunz C J Med Virol; 1994 Dec; 44(4):452-6. PubMed ID: 7897380 [TBL] [Abstract][Full Text] [Related]
36. [Evaluation of immunogenicity and safety in healthy adults of an inactivated anti-hepatitis A vaccine]. Gil A; González A; Dal-Ré ; Aguilar L; Malo C; del Rey J Med Clin (Barc); 1994 May; 102(20):769-71. PubMed ID: 8041214 [TBL] [Abstract][Full Text] [Related]
37. Safety, tolerability, and immunogenicity of an inactivated hepatitis A vaccine: effects of single and booster injections, and comparison to administration of immune globulin. Shouval D; Ashur Y; Adler R; Lewis JA; Miller W; Kuter B; Brown L; Nalin DR J Hepatol; 1993; 18 Suppl 2():S32-7. PubMed ID: 8182270 [TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and safety of an inactivated hepatitis A vaccine in Taiwanese adults and children. Lee CY; Huang LM; Lee PI; Chiu HH; Dumas R; Milcamps B; Lin W Southeast Asian J Trop Med Public Health; 2000 Mar; 31(1):29-36. PubMed ID: 11023061 [TBL] [Abstract][Full Text] [Related]
39. Protection against hepatitis A by an inactivated vaccine. Innis BL; Snitbhan R; Kunasol P; Laorakpongse T; Poopatanakool W; Kozik CA; Suntayakorn S; Suknuntapong T; Safary A; Tang DB JAMA; 1994 May; 271(17):1328-34. PubMed ID: 8158817 [TBL] [Abstract][Full Text] [Related]
40. A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks. Just M; Berger R; Dreschsler H; Brantschen S; Glück R Vaccine; 1992; 10(11):737-9. PubMed ID: 1441728 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]